Contents

Volume 42, Number 1, July 1996

Proceedings of the Festschrift in honour of Professor Sir Colin Dollery

1 Preface: *D. S. Davies*
3 Pathophysiology of asthma: *P. J. Barnes*
11 The asthma death problem revisited: *R. W. Fuller*
15 8-Epi $PGF_{2\alpha}$: specific analysis of an isoeicosanoid as an index of oxidant stress *in vivo*: *N. Delanty, M. Reilly, D. Pratico, D. J. Fitzgerald, J. A. Lawson & G. A. Fitzgerald*
21 The causes of essential hypertension: *M. J. Brown*
29 The treatment of hypertension: *J. Chalmers*
37 New therapeutic agents for hypertension: *J. L. Reid*
43 Transgenic mouse models in carcinogenesis: interaction of c-*myc* with transforming growth factor α and hepatocyte growth factor in hepatocarcinogenesis: *S. S. Thorgeirsson & E. Santoni-Rugiu*
53 A clinical pharmacologist's view of drug toxicity: *A. Breckenridge*
59 The clinical pharmacologist in drug regulation: a European perspective: *M. D. Rawlins*
63 Clinical pharmacologists and drug regulation – future perspective in Japan: *K. Hirokawa*
73 The clinical pharmacologist in drug regulation: the US perspective: *R. J. Temple*
81 Dissecting the function of P450: *A. R. Boobis, R. J. Edwards, D. A. Adams & D. S. Davies*
91 Heterocyclic amines: evaluation of their role in diet associated with human cancer: *N. J. Gooderham, S. Murray, A. M. Lynch, R. J. Edwards, M. Yadollahi-Farsani, C. Bratt, K. J. Rich, K. Zhao, B. P. Murray, S. Bhadresa, S. J. Crosbie, A. R. Boobis & D. S. Davies*
99 A possible role for mono(ADP-ribosyl) transferase in the signalling pathway mediating neutrophil chemotaxis: *J. R. Allport, L. E. Donnelly, P. Kefalas, G. Lo, A. Nunn, M. Yadollahi-Farsani, N. B. Rendell, S. Murray, G. W. Taylor & J. MacDermot*
107 Hypertensive cardiac hypertrophy – is genetic variance the missing link?: *D. J. R. Nunez, C. P. Clifford, S. Al-Mahdawi & D. Dutka*
119 Excursions in biomedical mass spectrometry: *G. W. Taylor, L. E. Donnelly, S. Murray & N. B. Rendell*
127 The regulation of pulmonary vascular tone: *M. R. Wilkins, L. Zhao & R. Al-Tubuly*
133 The clinical pharmacologist in drug discovery and development: *P. Lewis*
137 Clinical pharmacology: future prospects for the discipline: *C. Dollery*

Volume 42, Number 2, August 1996

Editorial

143 Multi-centre trials: U-turns by bandwagons and the patient left by the wayside: *S. M. Dobbs, R. J. Dobbs & A. Charlett*

Papers

147 Disposition of diazepam in young and elderly subjects after acute and chronic dosing: *R. J. Herman & G. R. Wilkinson*
157 Diazepam-omeprazole inhibition interaction: an *in vitro* investigation using human liver microsomes: *K. Zomorodi & J. B. Houston*
163 The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen: *K. J. Skeith, M. Dasgupta, R. Lange & F. Jamali*
171 Pharmacodynamics and pharmacokinetics of BAY x 7195 aerosol, a new and selective receptor antagonist of cysteinyl-leukotrienes, in normal volunteers: *G. Wensing, R. Heinig & J. Kuhlmann*
179 A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles: *L. L. Lewis*
187 Cholesterol lowering therapy inhibits the low-flow mediated vasoconstriction of the brachial artery in hypercholesterolaemic subjects: *J. L. Megnien, A. Simon, A. Andriani, P. Segond, S. Jeannin & J. Levenson*
195 Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response: *C. J. Haagsma, F. G. M. Russel, T. B. Vree, P. L. C. M. Riel & L. B. A. Van de Putte*
201 Pharmacokinetics of bismuth and ranitidine following single doses of ranitidine bismuth citrate: *K. M. Koch, J. M. Davis, A. E. Gooding & Y. Yin*
207 Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate: *K. M. Koch, B. M. Kerr, A. E. Gooding & I. M. Davis*
213 A cohort study of the ocular safety of anti-ulcer drugs: *L. A. García Rodríguez, S. Mannino, M-A. Wallander & B. Lindblom*
217 (–)-Timolol is a more potent antagonist of the positive inotropic effects of (–)-adrenaline than of those of (–)-noradrenaline in human atrium: *T. Wang, A. J. Kaumann & M. J. Brown*

225 The acute cardiovascular actions of intravenous thyrotrophin releasing hormone (TRH) in man are mediated by non-catecholamine mechanisms: *P-M. Bouloux, S. Corsello, M. Besser & A. Grossman*

Short reports

233 Calcium supplementation and ototoxicity in patients receiving cisplatin: *J. J. Grau, J. Estapé, M. A. Cuchi, J. L. Firvida, J. L. Blanch & C. Ascaso*

236 Effect of locally applied prazosin on the kinetics of the pupillary light reflex: *S-A. Mortlock, R. W. Langley, C. M. Bradshaw & E. Szabadi*

239 The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance: *J. S. Kerr, J. Powell & I. Hindmarch*

242 Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection: *J. X. Mazoit, D. Benhamou, Y. Veillette & K. Samii*

246 Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers: *J. D. Davis, R. Dixon, A. Z. Khan, S. Toon, P. E. Rolan & J. Posner*

249 Lack of pharmacokinetic interaction of pantoprazole with diazepam in man: *R. Gugler, M. Hartmann, J. Rudi, I. Brod, R. Huber, V. W. Steinijans, H. Bliesath, W. Wurst & U. Klotz*

253 Patient awareness of the adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs): *H. A. Wynne & A. Long*

Letter to the Editors

257 Lung bioavailability of chlorofluorocarbon free, dry powder and chloroflurocarbon containing formulations of salbutamol: *H. Chrystyn: B. J. Lipworth & D. J. Clark*

259 Proceedings of the British Pharmacological Society (The University of Leicester, 17–19 April 1996)

Volume 42, Number 3, September 1996

Reviews

283 Estimating impossible curves using NONMEM: *R. C. Schoemaker & A. F. Cohen*

291 Clinical pharmacology of β_3-adrenoceptors: *B. J. Lipworth*

Papers

301 The effect of age on the pharmacokinetics of the opioid antagonist nalmefene: *R. F. Frye, G. R. Matzke, N. S. Jallad, J. A. Wilhelm & G. B. Bikhazi*

307 A randomized, double-blind, placebo-controlled trial controlling pethidine to metamizol for treatment of post-anaesthetic shivering: *A. Monsó, J. Riudeubas, F. Barbal, J-R. Laporte & A. P. M. Arnau*

313 Taste loss to terbinafine: a case-control study of potential risk factors: *B. H. Ch. Stricker, M. M. Van Riemsdijk, M. C. J. M. Sturkenboom & J. P. Ottervanger*

319 A prospective study of adverse drug reactions as a cause of admission to a paediatric hospital: *I. Martínez-Mir, M. García-López, V. Palop, J. M. Ferrer, L. Estañ, E. Rubio & F. J. Morales-Olivas*

325 Single-dose pharmacokinetics of ampicillin and tobramycin administered by hyperdermoclysis in young and older healthy volunteers: *N. Champoux, P. Du Souich, M. Ravaoarinoro, D. Phaneuf, J. Latour & J. R. Cusson*

333 Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio: *G. De Pinieux, P. Chariot, M. Ammi-Said, F. Louarn, J. L. Lejonc, A. Astier, B. Jacotot & R. Gherardi*

339 Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration: *K. M. Sowinski, J. J. Lima, B. S. Burlew, J. D. Massie & J. A. Johnson*

347 The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole: *H. J. Gill, J. L. Maggs, S. Madden, M. Pirmohamed & B. K. Park*

355 Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control: *A. Souillard, M. Audran, F. Bressolle, R. Gareau, A. Duvallet & J.-L. Chanal*

365 γ-L-glutamyl-5-hydroxy-L-tryptophan, but not γ-L-glutamyl-L-tryptophan, causes sodium retention in normal man: *T. C. Li Kam Wa, S. Freestone, R. R. Samson, N. R. Johnson & M. R. Lee*

371 Suppression of vagus-mediated pancreatic polypeptide release by the μ-opiate receptor agonist loperamide in man: *R. L. Riepl, B. Reichardt, C. J. Auernhammer, G. Beier, J. Schopohl, G. K. Stalla & P. Lehnert*

379 Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus: *K. S. L. Lam, M. S. Wat, K. L. Choi, T. P. Ip, R. W. C. Pang & C. R. Kumana*

Short reports

387 Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue: *K. T. Kivistõ, G. Bookjans, M. F. Fromm, E.-U. Griese, P. Münzel & H. K. Kroemer*

390 Variable contribution of CYP2D6 to the *N*-dealkylation of S-(-)-propranolol by human liver microsomes: *K. Rowland, S. Wynne Ellis, M. S. Lennard & G. T. Tucker*

394 Influence of liver cirrhosis on sertraline pharmacokinetics: *J-L. Démolis, P. Angebaud, J-D. Grangé, P. Coates, C. Funck-Brentano & P. Jaillon*

Letters to the Editors

399 Drug-induced QT interval prolongation: *S. H. L. Thomas: M. Thomas, J. G. Maconochie & E. Fletcher*

401 Cross over trials: *P. R. Jackson & W. W. Yeo: T. J. M. Cleophas*

404 Parenteral administration of 8-methoxypsoralen: *R. M. Knobler & F. Trautinger: V. Billard & S. L. Shafer*

Book review

405 Handbook of Drugs for Tropical Parasitic Infections (2nd edn) by Y. A. Abdi, L. L. Gustafsson, O. Ericsson & U. Hellgren: *I. G. Edwards*

406 **Erratum**

Volume 42, Number 4, October 1996

Review

407 Drug toxicity and surveillance in children: *I. Choonara, A. Gill & A. Nunn*

Opinion

411 Mefloquine: the benefits outweigh the risks: *P. Winstanley*

Papers

415 Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial: *T. M. E. Davis, L. G. Dembo, S. A. Kaye-Eddie, B. J. Hewitt, R. G. Hislop & K. T. Batty*

423 Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines: *C. C. Smith, P. M. Bennett, H. M. Pearce, P. I. Harrison, D. J. M. Reynolds, J. K. Aronson & D. G. Grahame-Smith*

431 5-HT_{1D} receptor agonists and human coronary artery reactivity *in vitro*: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519: *J. Longmore, C. M. Boulanger, B. Desta, R. G. Hill, W. N. Schofield & A. A. Taylor*

443 Pharmacokinetics of trapidil, an antagonist of platelet derived growth factor, in healthy subjects and in patients with liver cirrhosis: *S. Harder, P. A. Thürmann, A. Hellstern & Anna Benjaminov*

451 Captopril has no significant scavenging antioxidant activity in human plasma *in vitro* or *in vivo*: *D. Lapenna, S. De Gioia, G. Ciofani, F. Daniele & F. Cuccurullo*

457 Inhibition of *ex vivo* neutrophil activation by oral LY293111, a novel leukotriene B_4 receptor antagonist: *P. Marder, S. M. Spaethe, L. L. Froelich, B. J. Cerimele, B. H. Petersen, T. Tanner & R. A. Lucas*

465 Effect of fluconazole dose on the extent of fluconazole-triazolam interaction: *A. Varhe, K. T. Olkkola & P. J. Neuvonen*

471 The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype: *J. Wan, H. Xia, N. He, Y-Q. Lu & H-H. Zhou*

475 Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary: *J. M. A. Van Gerven, R. C. Schoemaker, L-D. Jacobs, A. Reints, M. J. Ouwersloot-Van der Meij, H. G. J. Hoedemaker & A. F. Cohen*

483 Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a larger randomized placebo-controlled study: *A. C. Keech, J. M. Armitage, K. R. Wallendszus, A. Lawson, A. J. Hauer, S. E. Parish & R. Collins*

491 Double-blind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline: *J. G. Edwards, T. G. Dinan, D. G. Waller & S. G. Greentree*

Short reports

499 Assessment of changes in liver blood flow after food intake—comparison of ICG clearance and echo-Doppler: *J. Burggraaf, H. C. Schoemaker & A. F. Cohen*

503 Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers: *J. P. J. E. Sels, J. J. P. Nauta, P. P. C. A. Menheere, B. H. R. Wolffenbuttel & A. C. Nieuwenhuijzen Kruseman*

507 α-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility: *H. J. Marshall & D. G. Beevers*

510 Food intake and dosage level, but not tablet *vs* solution dosage form, affect the absorption of metformin HCl in man: *N. C. Sambol, L. G. Brookes, J. Chiang, A. M. Goodman, E. T. Lin, C. Y. Liu & L. Z. Benet*

513 Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine: *W. C. Shyu & R. H. Barbhaiya*

518 *In vivo* inhibition of CYP2C19 but not CYP2D6 by fluvoxamine: *Z-H. Xu, H-G. Xie & H-H. Zhou*

522 Effects of frusemide on the urinary excretion of dopamine and 5-hydroxytryptamine in normal man: *T. C. Li Kam Wa, S. Freestone, J. L. McCrindle, R. R. Samson, N. R. Johnston & M. R. Lee*

525 Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites: *L. Lennard, J. Welch & J. S. Lilleyman*

Letter to the Editor

529 CYP2E1 activity is not altered by influenza vaccination: *R. B. Kim & G. R. Wilkinson*

Volume 42, Number 5, November 1996

Review

531 The new generation of antiepileptic drugs: advantages and disadvantages: *E. Perucca*

Meeting report

545 Symposium on Pharmacogenetics

Papers

551 Drug and Therapeutics Committees in Australia: expected and actual performance: *L. M. Weekes & C. Brooks*

559 Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study: *D. P. O'Sullivan, C. A. Needham, A. Bangs, K. Atkin & F. D. Kendall*

567 Medicine taking in Southampton: a second look: *M. J. Sullivan & C. F. George*

573 Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan: *R. H. Barbhaiya, A. B. Buch & D. S. Greene*

583 Pharmacokinetics and pharmacodynamics of (±)-sotalol in healthy male volunteers: *M. Kimura, K. Umemura, Y. Ikeda, K. Kosuge, A. Mizuno, H. Nakanomyo, K. Ohashi & M. Nakashima*

589 Population pharmacokinetics of proguanil in patients with acute *P. falciparum* malaria after combined therapy with atovaquone: *Z. Hussein, C. J. Eaves, D. B. Hutchinson & C. J. Canfield*

599 Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay: *P. Teja-Isavadharm, F. Nosten, D. E. Kyle, C. Luxemburger, F. Ter Kuile, J. O. Peggins, T. G. Brewer & N. J. White*

605 The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine: *E. Snoeck, P. Jacqmin, A. Van Peer, M. Danhof, K. Ver Donck, H. Van Belle, R. Woestenborghs, R. Crabbé, R. Van Gool, A. Dupont & J. Heykants*

615 Pharmacokinetics and haemodynamic effects of the angiotensin converting enzyme inhibitor cilazapril in hypertensive patients with normal and impaired renal function: *H. J. Kloke, R. J. Ambros, H. W. Van Hamersvelt, J. F. M. Wetzels, R. A. P. Koene & F. T. M. Huysmans*

621 Effects of lamotrigine on EEG paroxysmal abnormalities and background activity: a computerized analysis: *M. G. Marciani, F. Spanedda, M. A. Bassetti, M. Maschio, G. L. Gigli, D. Mattia & G. Bernardi*

Short reports

629 Effect of intravenous magnesium sulphate on airway calibre and airway reactivity to histamine in asthmatic subjects: *J. M. Hill & J. Britton*

632 Lack of gender effect on ciprofloxacin pharmacokinetics in humans: *K. Gallicano & J. Sahai*

635 A single sample saliva test to determine acetylator phenotype: *A. D. Hutchings & P. A. Routledge*

638 Erythrocyte thiopurine methyltransferase activity in a Korean population: *I. J. Jang, S. G. Shin, K. H. Lee, D. S. Yim, M. S. Lee, H. H. Koo, H. K. Kim & D. R. Sohn*

642 Diltiazem does not always increase blood cyclosporin concentration: *T. E. Jones & R. G. Morris*

Letter to the Editor

645 Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations, Oramorph SR and MST Continus: *A. J. Miller & K. J. Smith: J. Drake, C. E. Horth & F. E. Crawford*

Proceedings

649 Proceedings of the British Pharmacological Society (10–12 July 1996, University of Bath)

Volume 42, Number 6, December 1996

Editorial

681 Thrombolysis for stroke: pushed out of the window?: *K. W. Muir*

Reviews

683 Genes, disease and medicine: *C. W. Dykes*

697 Pharmacokinetics of inhaled drugs: *B. J. Lipworth*

Papers

707 Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans: *Y. Böttiger, P. Dostert, M. Strolin Benedetti, M. Bani, F. Fiorentini, M. Casati, I. Poggesti, C. Alm, G. Alvan & L. Bertilsson*

713 A novel mutant variant of the *CYP2D6* gene (*CYP2D6*17*) common in a black African population: association with diminished debrisoquine hydroxylase activity: *C. Masimirembwa, I. Persson, L. Bertilsson, J. Hasler & M. Ingelman-Sundberg*

721 Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: Interaction with low dose acetylsalicylic acid: *R. H. Böger, S. M. Bode-Böger, P. Kramme, D. Tsikas, F-M. Gutzki & J. C. Frölich*

729 Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine: *C. H. Gleiter, S. Freudenthaler, U. Delabar, K. U. Eckardt, B. Mühlbauer, U. Gundert-Remy & H. Osswald*

737 A method for simultaneous determination of plasma and erythrocyte antioxidant status. Evaluation of the antioxidant activity of vitamin E in healthy volunteers: *A. Abella, C. Messaoudi, D. Laurent, D. Marot, J. Chalas, J. Breux, C. Claise & A. Lindenbaum*

743 Effect of food on the absorption of frusemide and bumetanide in man: *J. L. McCrindle, T. C. Li Kam Wa, W. Barron & L. F. Prescott*

747 Characterization and validation of a pharmacokinetic model for controlled-release oxycodone: *J. W. Mandema, R. F. Kaiko, B. Oshlack, R. F. Reder & D. R. Stanski*

757 A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal: *J. S. Price, P. C. Waller, S. M. Wood & A. V. P. MacKay*

765 Clinical drug monitoring by microdialysis: application to levodopa therapy in Parkinson's disease: *M. T. O'Connell, F. Tison, N. P. Quinn & P. N. Patsalos*

Short reports

771 Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population: *N. E. Basci, A. Bozkurt, S. Kortunay, A. Isimer, A. Sayal & S. O. Kayaalp*

774 Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity *in vivo*: *W. Tassaneeyakul, D. J. Birkett, M. C. Pass & J. O. Miners*

779 Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures: *F. Vauzelle-Kervroëdan, E. Rey, G. Pons, Ph. d'Athis, C. Chiron, O. Dulac, C. Dumas & G. Olive*

782 Effects of picotamide, an antiplatelet agent, on cardiovascular events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study: *M. Milani, A. Longoni & M. Maderna*

Letter to the Editors

787 Improved tolerability of ritonavir derived from pharmacokinetic principles: *C. Merry, M. Barry, S. Gibbons, F. Mulcahy & D. Back*

789 **List of Referees**

791 **Indexes to Volume 42**